SCHEMBL22609513

SCHEMBL22609513

O=C1CCCC(=O)N1n1cnc2ccccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 1/20 0.41
▸ CRBN Q96SW2 1/20 0.41
▸ IKZF3 Q9UKT9 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ HTT P42858 3/20 0.40
▸ LMNA P02545 2/20 0.38
▸ TSHR P16473 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ GGPS1 O95749 1/20 0.38
▸ FDPS P14324 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ MKNK1 Q9BUB5 2/20 0.37
▸ MKNK2 Q9HBH9 2/20 0.37
▸ PDE2A O00408 1/20 0.37
▸ PDE3B Q13370 1/20 0.37
▸ PDE3A Q14432 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ TNF P01375 1/20 0.37
▸ CYP11B1 P15538 1/20 0.37
▸ CYP11B2 P19099 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29991276 1.00 DDB1 (0.41) DDB1CRBNIKZF3TDP1HTT
SCHEMBL9449531 0.77 TDP1 (0.44) DDB1CRBNIKZF3TDP1HTT
SCHEMBL7196401 0.75 TDP1 (0.58) TDP1HTTLMNAPOLBTNF
SCHEMBL21047640 0.73 MKNK1 (0.42) DDB1CRBNIKZF3TDP1HTT
SCHEMBL31282147 0.73 DDB1 (0.40) DDB1CRBNIKZF3HTTLMNA
SCHEMBL21047632 0.72 MKNK1 (0.42) DDB1CRBNIKZF3TDP1HTT
SCHEMBL4553023 0.72 TDP1 (0.46) TDP1HTTLMNATSHRNPSR1
SCHEMBL21047798 0.71 MKNK1 (0.46) DDB1CRBNIKZF3TDP1HTT
SCHEMBL739312 0.70 GAA (0.47) TDP1HTTLMNATSHRNPSR1
SCHEMBL29991297 0.70 GAA (0.47) TDP1HTTLMNATSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4334307-A1 CDK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-03-13 — — EP disclosed
EP-4121043-A1 MDM2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2023-01-25 — — EP disclosed
WO-2021188948-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-09-23 — — WO disclosed
EP-3731869-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2020-11-04 — — EP disclosed
Send feedback